Table 2.
Linear mixed modeling estimates of fibroblast ROS inhibition and migration rate for each treatment, relative to untreated scratched controls (negative co-efficient for ROS activity corresponds with more inhibition).
| Treatment | ROS activity compared to controls | Migration rate | p < 0.05 |
|---|---|---|---|
| FIBROBLASTS | |||
| Mitoquinone | −0.458 | 0.255 | * |
| Linezolid | −0.307 | 0.110 | * |
| Clindamycin | −0.300 | 0.172 | * |
| Erythromycin | −0.277 | 0.102 | * |
| Ciprofloxacin | −0.236 | 0.163 | * |
| Tedizolid | −0.229 | 0.076 | * |
| Roxithromycin | −0.227 | 0.252 | * |
| Azithromycin | −0.224 | 0.132 | |
| Augmentin | −0.201 | 0.129 | * |
| Clarithromycin | −0.187 | 0.294 | * |
| Mupirocin | −0.124 | 0.095 | * |
| Doxycycline | −0.122 | 0.276 | |
P-values indicate a significant relationship between the two for the given treatment
(*
p < 0.05). Values and treatments sorted by inhibition of ROS activity. Treatments in bold also showed a significant reduction in wound closure time compared to untreated wounds.